[go: up one dir, main page]

CY1120087T1 - Συνθεση εξωκυτταριας θεμελιας ουσιας (ecm, extra cellular matrix), πλατφορμα μικροπεριβαλλοντος ογκου και οι μεθοδοι τους - Google Patents

Συνθεση εξωκυτταριας θεμελιας ουσιας (ecm, extra cellular matrix), πλατφορμα μικροπεριβαλλοντος ογκου και οι μεθοδοι τους

Info

Publication number
CY1120087T1
CY1120087T1 CY20181100194T CY181100194T CY1120087T1 CY 1120087 T1 CY1120087 T1 CY 1120087T1 CY 20181100194 T CY20181100194 T CY 20181100194T CY 181100194 T CY181100194 T CY 181100194T CY 1120087 T1 CY1120087 T1 CY 1120087T1
Authority
CY
Cyprus
Prior art keywords
tumor
ecm
addition
disclosure relates
composition
Prior art date
Application number
CY20181100194T
Other languages
English (en)
Inventor
Mallikarjun Sundaram
Biswanath MAJUMDER
Misti JAIN
Saravanan THIAGARAJAN
Dency PINTO
Padhma RADHAKRISHNAN
Original Assignee
Mitra Rxdx India Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitra Rxdx India Private Limited filed Critical Mitra Rxdx India Private Limited
Publication of CY1120087T1 publication Critical patent/CY1120087T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα γνωστοποίηση αναφέρεται στη σύνθεση Εξωκυττάριας Θεμέλιας Ουσίας (ECM) ειδική για τύπο καρκίνου και πλατφόρμα μικροπεριβάλλοντος όγκου για τη μακροχρόνια καλλιέργεια ιστού όγκου, όπου η εν λόγω καλλιέργεια παρέχει ανθρώπινες συνδέτες και μικροπεριβάλλον του ιστού όγκου προκειμένου να μιμηθεί φυσιολογικά τα σχετικά συστήματα σηματοδότησης. Επιπλέον η παρούσα γνωστοποίηση αναφέρεται στην ανάπτυξη Προγνωστικού Παράγοντα Κλινικής Απόκρισης (Προγνωστικό Παράγοντα Κλινικής Απόκρισης) και στην εφαρμογή της στο πεδίο της πρόγνωσης (επιλογή εναλλακτικών θεραπείας για τον ασθενή) και στο πεδίο της μεταγραφικής βιολογίας (ανάπτυξη αντικαρκινικών φαρμάκων). Επιπλέον η γνωστοποίηση αναφέρεται σε μέθοδο για την πρόβλεψη της κλινικής απόκρισης σε φάρμακα ασθενούς με όγκο. Επιπλέον η γνωστοποίηση αναφέρεται σε μέθοδο για τον έλεγχο των κυττάρων του όγκου για την ύπαρξη συγκεκριμένων δεικτών για τον προσδιορισμό της βιωσιμότητας των εν λόγω κυττάρων ως ένδειξη της κατάστασης του όγκου.
CY20181100194T 2011-10-04 2018-02-21 Συνθεση εξωκυτταριας θεμελιας ουσιας (ecm, extra cellular matrix), πλατφορμα μικροπεριβαλλοντος ογκου και οι μεθοδοι τους CY1120087T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3310CH2011 2011-10-04
PCT/IB2012/055334 WO2013050962A1 (en) 2011-10-04 2012-10-04 Ecm composition, tumor microenvironment platform and methods thereof

Publications (1)

Publication Number Publication Date
CY1120087T1 true CY1120087T1 (el) 2018-12-12

Family

ID=54261176

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100194T CY1120087T1 (el) 2011-10-04 2018-02-21 Συνθεση εξωκυτταριας θεμελιας ουσιας (ecm, extra cellular matrix), πλατφορμα μικροπεριβαλλοντος ογκου και οι μεθοδοι τους

Country Status (14)

Country Link
US (7) US20140228246A1 (el)
EP (1) EP2764099B1 (el)
JP (2) JP6147259B2 (el)
AU (1) AU2012320088C1 (el)
CA (1) CA2850274A1 (el)
CY (1) CY1120087T1 (el)
DK (1) DK2764099T3 (el)
ES (1) ES2660975T3 (el)
HU (1) HUE036537T2 (el)
NO (1) NO2764099T3 (el)
PT (1) PT2764099T (el)
SG (1) SG11201401183UA (el)
TR (1) TR201802420T4 (el)
WO (1) WO2013050962A1 (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105593438B (zh) 2013-05-31 2019-07-05 伊顿智能动力有限公司 用于通过平衡保护来降低动臂跳动的液压系统及方法
EP3074028B1 (en) * 2013-11-27 2022-04-06 Research Foundation Of The City University Of New York Activity enhancing curcumin compositions and methods of use
CN103966168B (zh) * 2014-05-19 2017-05-03 广州恒迪生物科技有限公司 肿瘤活组织体外培养系统及培养方法
US10745667B2 (en) 2015-03-23 2020-08-18 Yao Tang Methods of primary tissue culture and drug screening using autologous serum and fluids
JP6135795B2 (ja) * 2015-04-22 2017-05-31 小野薬品工業株式会社 リード化合物の抽出方法、創薬ターゲットの選択方法及び散布図生成装置並びにデータの可視化方法及び可視化装置
GB201507894D0 (en) * 2015-05-08 2015-06-24 Imagen Biotech Ltd Personalised media
CN108138146A (zh) 2015-10-20 2018-06-08 凯尔科迪公司 制备原代细胞样品的方法
CN106047788A (zh) * 2016-08-22 2016-10-26 上海逍鹏生物科技有限公司 一种适用于高密度细胞培养体系的培养基
GB2555787A (en) * 2016-11-07 2018-05-16 Landberg Goran Diagnostic methods
WO2018148334A1 (en) * 2017-02-08 2018-08-16 Mitra Rxdx, Inc. Method of predicting clinical outcome of anticancer agents
JP7616798B2 (ja) 2017-04-05 2025-01-17 イェダ リサーチ アンド ディベロップメント カンパニー リミテッド エクスビボ培養系およびその使用方法
IL257225A (en) 2018-01-29 2018-04-09 Yeda Res & Dev Treatment of sarcoma
WO2019164951A1 (en) * 2018-02-22 2019-08-29 Mitra Rxdx, Inc. Methods of predicting response to temporally sequenced combination therapy
GB201818885D0 (en) 2018-11-20 2019-01-02 Precomb Therapeutics Ag 3d human cancer model-based combinatiorial drug development method
WO2020172591A1 (en) * 2019-02-22 2020-08-27 Mitra Rxdx, Inc. A method to predict a patient's response to an anti-cancer drug from an expression level of a set of genes
WO2020191105A2 (en) * 2019-03-19 2020-09-24 Kyuson Yun Methods and systems for evaluation of cell samples
CN112961830A (zh) * 2021-02-25 2021-06-15 重庆医科大学附属口腔医院 口腔鳞癌组织脱细胞基质及其制备方法和应用
CA3219233A1 (en) 2021-06-06 2022-12-15 Ravid STRAUSSMAN Combined treatment for cancer
CN113774025B (zh) * 2021-08-26 2023-07-14 湖南丰晖生物科技有限公司 一种结直肠癌顺铂耐药株的构建方法
WO2023067582A1 (en) * 2021-10-23 2023-04-27 Mazumdar Shaw Medical Foundation Tumor microenvironment platform comprising oral carcinoma for predicting drug sensitivity, drug resistance and disease progression
US12312631B1 (en) 2022-06-15 2025-05-27 SageMedic Corporation High-throughput multiplexed sensitivity and resistance assay
PL444462A1 (pl) * 2023-04-18 2024-10-21 Uniwersytet Medyczny W Białymstoku Sposób oceny chemiowrażliwości komórek nowotworowych in vitro na leki przeciwnowotworowe i sposób diagnostyki ex vivo nowotworu piersi

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508188A (en) * 1994-01-21 1996-04-16 The Regents Of The University Of California Method of growing cells in a mammal
FR2842822B1 (fr) * 2002-07-26 2004-10-01 Roussy Inst Gustave Procede de preparation d'une matrice extracellulaire et son utilisation pour la culture de cellules tumorales
US8071135B2 (en) * 2006-10-04 2011-12-06 Anthrogenesis Corporation Placental tissue compositions
WO2010120329A1 (en) * 2009-04-15 2010-10-21 The University Of Medicine And Dentistry Of New Jersey Reconstituted tumor microenvironment for anticancer drug development
WO2011148669A1 (ja) * 2010-05-25 2011-12-01 株式会社 島津製作所 大腸がんマーカービトロネクチン、及び採血試料中のビトロネクチン濃度の分析方法

Also Published As

Publication number Publication date
EP2764099A1 (en) 2014-08-13
SG11201401183UA (en) 2014-09-26
ES2660975T3 (es) 2018-03-26
AU2012320088B9 (en) 2015-07-16
WO2013050962A1 (en) 2013-04-11
AU2012320088C1 (en) 2016-03-17
US20190383795A1 (en) 2019-12-19
EP2764099B1 (en) 2017-11-22
US20190346428A1 (en) 2019-11-14
TR201802420T4 (tr) 2018-03-21
US20200064333A1 (en) 2020-02-27
EP2764099A4 (en) 2015-05-06
CA2850274A1 (en) 2013-04-11
JP6147259B2 (ja) 2017-06-14
JP6378273B2 (ja) 2018-08-22
US20140228246A1 (en) 2014-08-14
US20190353640A1 (en) 2019-11-21
HUE036537T2 (hu) 2018-07-30
AU2012320088B2 (en) 2015-07-02
US20190383796A1 (en) 2019-12-19
NO2764099T3 (el) 2018-04-21
US20190170730A1 (en) 2019-06-06
DK2764099T3 (en) 2018-02-26
JP2014534809A (ja) 2014-12-25
AU2012320088A1 (en) 2014-05-01
PT2764099T (pt) 2018-02-28
JP2017061448A (ja) 2017-03-30

Similar Documents

Publication Publication Date Title
CY1120087T1 (el) Συνθεση εξωκυτταριας θεμελιας ουσιας (ecm, extra cellular matrix), πλατφορμα μικροπεριβαλλοντος ογκου και οι μεθοδοι τους
Hass et al. Impact of the tumor microenvironment on tumor heterogeneity and consequences for cancer cell plasticity and stemness
Ziółkowska-Suchanek Mimicking tumor hypoxia in non-small cell lung cancer employing three-dimensional in vitro models
Wu et al. Role of cancer stem cells in cholangiocarcinoma and therapeutic implications
Burute et al. Polarity reversal by centrosome repositioning primes cell scattering during epithelial-to-mesenchymal transition
Rae et al. Patient-derived organoids as a model for cancer drug discovery
Damaghi et al. Phenotypic changes of acid-adapted cancer cells push them toward aggressiveness in their evolution in the tumor microenvironment
Singh et al. Three-dimensional breast cancer models mimic hallmarks of size-induced tumor progression
CN105143883B (zh) 基于细胞的药物筛选分析方法和其用途
GB2531881A (en) Method of isolating circulating tumor cells
Xie et al. Single‐cell RNA sequencing elucidated the landscape of breast cancer brain metastases and identified ILF2 as a potential therapeutic target
BR112014028881A2 (pt) populações de células, banco de células, métodos de obtenção de uma população de células, métodos de identificação de um fator, métodos de seleção, métodos de fornecimento de terapia, populações de hepatócitos e método de obtenção de células
MX380588B (es) Ratones de m-csf humanizada.
Rios et al. The complexities and caveats of lineage tracing in the mammary gland
EP4083233A3 (en) Method for using gene expression to determine prognosis of prostate cancer
Abugomaa et al. Patient-derived organoid analysis of drug resistance in precision medicine: is there a value?
WO2014071279A3 (en) Gene fusions and alternatively spliced junctions associated with breast cancer
Dominijanni et al. Manipulating the tumor microenvironment in tumor organoids induces phenotypic changes and chemoresistance
BR112014004543A2 (pt) método de síntese de proteínas
BRPI0908747A2 (pt) Ligantes esteróides e seu uso em modulação de comutador genético
Lorusso et al. miRNAs as key players in the management of cutaneous melanoma
EP2619587A4 (en) BIOMARKER FOR PREDICTING THE REPRODUCTION OF A COLORECTAL CARCINOMA
Singh et al. Controlled three-dimensional tumor microenvironments recapitulate phenotypic features and differential drug response in early vs advanced stage breast cancer
Krysko et al. In vitro veritas: from 2D cultures to organ-on-a-chip models to study immunogenic cell death in the tumor microenvironment
Vella et al. 3D cell culture models in research: applications to lung cancer pharmacology